Pharmsville Co Ltd

Pharmsville Co Ltd maintains a strong liquidity position with a current ratio of 21.76, indicating a significant buffer of current assets relative to current liabilities. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of 1.67 billion KRW and a free cash flow of 2.61 billion KRW. The company's price-to-book ratio of 0.43 suggests that the market values the company at a discount to its book value. In terms of profitability, Pharmsville's return on equity (ROE) of 4.35% and return on assets (ROA) of 4.22% are below the industry median for Food Processing, which typically sees ROE and ROA in the 6-8% range. The company's operating income is negative at -673.13 million KRW, indicating operational inefficiencies or high costs relative to revenue. Gross profit of 8.06 billion KRW represents a 63.3% margin, which is in line with the industry average for health functional foods. Pharmsville's revenue is concentrated in the health functional foods segment, with no disclosed geographic diversification in the latest financials. The company operates primarily in South Korea, and its e-commerce and distribution platforms are the primary channels for revenue generation. There is no indication of significant international expansion or diversification in the latest filings. The company's revenue growth trajectory is mixed. While the latest reported revenue of 12.73 billion KRW is below the analyst estimate of 39.41 billion KRW, the company's free cash flow and operating cash flow remain positive. The company's capital expenditure of -70.51 million KRW suggests a reduction in investment in physical assets, which may indicate a focus on cost control or a shift toward digital or service-based operations. The outlook for the current fiscal year is uncertain, with no clear direction provided in the latest filings. Pharmsville's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.0, indicating no long-term debt obligations. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal at 7.73 million. The company's valuation adjustments do not indicate any material changes in valuation assumptions. Recent events include the latest financial filing, which shows a net income of 2.89 billion KRW despite a negative operating income. The company's market price of 3,700 KRW and market cap of 28.59 billion KRW suggest a relatively small market presence. There are no recent transcripts or filings indicating significant strategic shifts or new product launches.